Choksi Laboratories Limited has appointed Ankit Consultancy Private Limited as its new Registrar and Share Transfer Agent (RTA), replacing MUFG Intime India Private Limited effective August 03, 2026. The company stated that the decision followed a comprehensive evaluation of service offerings, technological capabilities, and local convenience. This operational shift ensures continued electronic connectivity with the depositories for share transfers and related services.

The change in RTA was executed in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Choksi Laboratories submitted the intimation to BSE Limited on August 03, 2026, referencing SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. The company confirmed that electronic connectivity with both National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL) was transferred to the new agent on the effective date.

Key Details of the Transition

Confirmations from the depositories validate the switch. NSDL notified the company on July 31, 2026, stating that MUFG Intime would cease acting as the RTA for electronic connectivity w.e.f. the beginning of the day on August 03, 2026, while Ankit Consultancy would commence operations on the same date. CDSL confirmed in a letter dated August 03, 2026, that it had effected the change in its system, noting that the tripartite agreement with the previous RTA stands cancelled.

Procedural Compliance and Next Steps

Under Regulation 7 of the Listing Regulations, Choksi Laboratories is required to execute a Tripartite Agreement between the company, MUFG Intime India Private Limited, and Ankit Consultancy Private Limited. The company indicated that this agreement will be executed in due course and intimated to the stock exchanges within statutory timelines from the date of signing.

Prakhar Dubey, Company Secretary and Compliance Officer of Choksi Laboratories, signed the disclosure. The company has made this information available on its website, www.choksilab.in , ensuring transparency for investors regarding the administrative change in share transfer handling.

Choksi Laboratories Limited reported a 29% increase in net profit to ₹196.43 lakh for the financial year ended March 31, 2026, compared to ₹152.33 lakh in the previous year. The company's revenue from operations for FY26 stood at ₹4600.59 lakh, up from ₹4178.23 lakh in FY25. The Board of Directors approved the audited financial results during a meeting held on May 25, 2026, and the results were published in newspapers on May 26, 2026, in compliance with Regulation 47 of the SEBI (LODR) Regulations, 2015.

Financial Performance

For the quarter ended March 31, 2026, the company recorded a net profit of ₹102.68 lakh, compared to ₹92.13 lakh in the corresponding quarter of the previous year. Total revenue for the year ended March 31, 2026, reached ₹4621.93 lakh. Profit before tax for the year was ₹319.46 lakh, higher than the ₹215.33 lakh recorded in the preceding financial year. The basic and diluted earnings per share (EPS) for the year were ₹2.82, compared to ₹2.19 in the previous year.

Operational Details

Choksi Laboratories identified "Analysis and Testing" as its single operating segment. The statutory auditors, M/s Prateek Jain & Co., Chartered Accountants, issued an unmodified opinion on the financial results. During the quarter, the company sold an office flat, resulting in a gain of ₹75.30 lakh, which was disclosed as an exceptional item.

Assets and Cash Flow

As of March 31, 2026, the company's total assets were valued at ₹7192.08 lakh, an increase from ₹6533.21 lakh in the previous year. Total equity stood at ₹2557.54 lakh, while total liabilities were recorded at ₹4634.54 lakh. Cash and cash equivalents at the end of the financial year stood at ₹20.67 lakh. Net cash generated from operating activities was ₹786.48 lakh, while investing activities resulted in a net cash outflow of ₹707.46 lakh.